Achao­gen’s bank­rupt­cy and go­ing-out-of-busi­ness sale of­fer a grim cau­tion­ary tale for the fu­ture of an­tibi­ot­ic de­vel­op­ment

The lights are wink­ing out at Achao­gen, of­fer­ing an­oth­er cau­tion­ary tale that will make it even less like­ly we’ll see new com­pa­nies come along to de­vel­op an­tibi­otics — even as drug-re­sis­tant strains of bac­te­ria pose a ris­ing threat to the world’s pop­u­la­tion.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.